Carregant...
Recent advances in antimultiple myeloma drug development
Multiple myeloma (MM) is the second most common hematological malignancy and is characterized by the aberrant proliferation of terminally differentiated plasma B cells with impairment in apoptosis capacity. Particularly, osteolytic bone diseases and renal failure resulting from hyperparaproteinemia...
Guardat en:
| Publicat a: | Pharm Pat Anal |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4465869/ https://ncbi.nlm.nih.gov/pubmed/24998287 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4155/ppa.14.18 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|